Stock analysts at Royal Bank Of Canada began coverage on shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) in a report released on Thursday. The brokerage set an “outperform” rating and a $78.00 price target on the biopharmaceutical company’s stock. Royal Bank Of Canada’s target price would indicate a potential upside of 17.42% from the company’s previous close.

A number of other research analysts have also weighed in on the stock. ValuEngine raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and issued a $83.00 price objective (up from $75.00) on shares of Agios Pharmaceuticals in a research note on Thursday, August 10th. Needham & Company LLC raised their price objective on shares of Agios Pharmaceuticals from $54.00 to $72.00 and gave the company a “buy” rating in a research note on Thursday, August 10th. BidaskClub lowered shares of Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, August 9th. Finally, Canaccord Genuity set a $90.00 price objective on shares of Agios Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, August 8th. Four investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Agios Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $75.11.

Shares of Agios Pharmaceuticals (AGIO) opened at 66.43 on Thursday. The company’s market capitalization is $3.21 billion. The firm’s 50-day moving average is $60.25 and its 200 day moving average is $54.45. Agios Pharmaceuticals has a 12 month low of $39.24 and a 12 month high of $67.74.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.57) by ($0.21). Agios Pharmaceuticals had a negative net margin of 502.12% and a negative return on equity of 68.15%. The business had revenue of $11.30 million during the quarter, compared to the consensus estimate of $10.68 million. During the same period last year, the business posted ($1.47) earnings per share. The firm’s quarterly revenue was up 62.1% on a year-over-year basis. Equities research analysts predict that Agios Pharmaceuticals will post ($7.07) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another publication, it was illegally copied and reposted in violation of United States & international trademark and copyright laws. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/16/agios-pharmaceuticals-inc-agio-now-covered-by-royal-bank-of-canada.html.

In related news, CEO David P. Schenkein sold 27,000 shares of the firm’s stock in a transaction dated Wednesday, August 2nd. The shares were sold at an average price of $59.95, for a total transaction of $1,618,650.00. Following the transaction, the chief executive officer now directly owns 3,000 shares of the company’s stock, valued at $179,850. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Lewis Clayton Jr. Cantley sold 4,000 shares of the firm’s stock in a transaction dated Thursday, September 14th. The shares were sold at an average price of $65.59, for a total transaction of $262,360.00. Following the transaction, the director now directly owns 86,394 shares in the company, valued at $5,666,582.46. The disclosure for this sale can be found here. Insiders have sold 104,230 shares of company stock worth $6,245,972 over the last three months. 10.55% of the stock is owned by insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in AGIO. Teachers Advisors LLC lifted its position in shares of Agios Pharmaceuticals by 22.7% during the fourth quarter. Teachers Advisors LLC now owns 29,592 shares of the biopharmaceutical company’s stock valued at $1,235,000 after purchasing an additional 5,467 shares in the last quarter. Bank of Montreal Can lifted its position in shares of Agios Pharmaceuticals by 11.7% during the first quarter. Bank of Montreal Can now owns 2,068 shares of the biopharmaceutical company’s stock valued at $121,000 after purchasing an additional 216 shares in the last quarter. Nationwide Fund Advisors lifted its position in shares of Agios Pharmaceuticals by 5.2% during the first quarter. Nationwide Fund Advisors now owns 10,104 shares of the biopharmaceutical company’s stock valued at $590,000 after purchasing an additional 500 shares in the last quarter. Janney Montgomery Scott LLC bought a new position in shares of Agios Pharmaceuticals during the first quarter valued at about $257,000. Finally, Russell Investments Group Ltd. lifted its position in shares of Agios Pharmaceuticals by 163.9% during the first quarter. Russell Investments Group Ltd. now owns 2,549 shares of the biopharmaceutical company’s stock valued at $149,000 after purchasing an additional 1,583 shares in the last quarter. 94.30% of the stock is currently owned by institutional investors.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Analyst Recommendations for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Stock Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.